AU2003242771B2 - Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase - Google Patents

Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase Download PDF

Info

Publication number
AU2003242771B2
AU2003242771B2 AU2003242771A AU2003242771A AU2003242771B2 AU 2003242771 B2 AU2003242771 B2 AU 2003242771B2 AU 2003242771 A AU2003242771 A AU 2003242771A AU 2003242771 A AU2003242771 A AU 2003242771A AU 2003242771 B2 AU2003242771 B2 AU 2003242771B2
Authority
AU
Australia
Prior art keywords
amino
oxo
quinazoline
chloro
buten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003242771A
Other languages
English (en)
Other versions
AU2003242771A1 (en
Inventor
Christopher John Montague Meade
Michel Pairet
Michael P. Pieper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of AU2003242771A1 publication Critical patent/AU2003242771A1/en
Application granted granted Critical
Publication of AU2003242771B2 publication Critical patent/AU2003242771B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2003242771A 2002-07-09 2003-06-26 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase Ceased AU2003242771B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10230751.2 2002-07-09
DE10230751A DE10230751A1 (de) 2002-07-09 2002-07-09 Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
PCT/EP2003/006788 WO2004004775A1 (de) 2002-07-09 2003-06-26 Neue arzneimittelkompositionen auf der basis neuer anticholinergika und egfr-kinase hemmern

Publications (2)

Publication Number Publication Date
AU2003242771A1 AU2003242771A1 (en) 2004-01-23
AU2003242771B2 true AU2003242771B2 (en) 2009-07-30

Family

ID=29761746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003242771A Ceased AU2003242771B2 (en) 2002-07-09 2003-06-26 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase

Country Status (16)

Country Link
EP (2) EP1521595B1 (enExample)
JP (1) JP2005537250A (enExample)
CN (1) CN1665539A (enExample)
AT (1) ATE320269T1 (enExample)
AU (1) AU2003242771B2 (enExample)
BR (1) BR0312507A (enExample)
CA (1) CA2492037A1 (enExample)
DE (2) DE10230751A1 (enExample)
ES (1) ES2259769T3 (enExample)
MX (1) MXPA05000163A (enExample)
NZ (1) NZ538096A (enExample)
PL (1) PL374022A1 (enExample)
RU (1) RU2317828C2 (enExample)
TW (1) TW200520757A (enExample)
WO (1) WO2004004775A1 (enExample)
ZA (1) ZA200409676B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239410B2 (en) 2000-10-31 2008-05-01 Eisai Inc. CYP1B1 nucleic acids and methods of use
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
EP1781298B1 (de) * 2004-04-22 2012-01-04 Boehringer Ingelheim International GmbH Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
EP1917253B1 (de) 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368583A1 (en) * 1999-05-12 2000-11-23 Boehringer Ingelheim Pharma Kg New medicament compositions based on anticholinergically-effective compounds and .beta.-mimetics
CA2375259A1 (en) * 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO2002032899A1 (de) * 2000-10-14 2002-04-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue als arzneimittel einsetzbare anticholinergika sowie verfahren zu deren herstellung
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2927925A (en) * 1960-03-08 Scopine and sgopoline esters of alpha
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536903C2 (de) 1995-10-04 1998-09-10 Boehringer Ingelheim Int Vorrichtung zum Haltern eines fluidischen Bauteils
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19545226C1 (de) 1995-12-05 1997-06-19 Boehringer Ingelheim Int Sperrspannwerk für einen federbetätigten Abtrieb
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
DE10206505A1 (de) * 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368583A1 (en) * 1999-05-12 2000-11-23 Boehringer Ingelheim Pharma Kg New medicament compositions based on anticholinergically-effective compounds and .beta.-mimetics
CA2375259A1 (en) * 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
WO2002032899A1 (de) * 2000-10-14 2002-04-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue als arzneimittel einsetzbare anticholinergika sowie verfahren zu deren herstellung

Also Published As

Publication number Publication date
TW200520757A (en) 2005-07-01
DE50302675D1 (de) 2006-05-11
ATE320269T1 (de) 2006-04-15
PL374022A1 (en) 2005-09-19
BR0312507A (pt) 2005-04-12
WO2004004775A1 (de) 2004-01-15
JP2005537250A (ja) 2005-12-08
EP1658860A1 (de) 2006-05-24
ES2259769T3 (es) 2006-10-16
AU2003242771A1 (en) 2004-01-23
EP1521595A1 (de) 2005-04-13
NZ538096A (en) 2007-04-27
CA2492037A1 (en) 2004-01-15
RU2005103397A (ru) 2006-03-20
ZA200409676B (en) 2006-05-31
RU2317828C2 (ru) 2008-02-27
CN1665539A (zh) 2005-09-07
MXPA05000163A (es) 2005-04-08
EP1521595B1 (de) 2006-03-15
DE10230751A1 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
US20030158196A1 (en) Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7776315B2 (en) Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20040048887A1 (en) Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20040058950A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020193393A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20110076238A1 (en) Compounds for the treatment of proliferative processes
US20100310477A1 (en) Pharmaceutical compositions based on anticholingerics and additional active ingredients
US20040002502A1 (en) Medicament combinations comprising heterocyclic compounds and a novel anticholinergic
US20040048886A1 (en) Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists
US20030203918A1 (en) Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound
AU2003206881B2 (en) New medicinal compositions on the basis of anticholinergic agents and EGFR kinase inhibitors
ZA200406751B (en) Medicaments containing steroids and a novel anticholinesterase drug
AU2003242771A1 (en) Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase
US20060239935A1 (en) Compositions for inhalation
CA2492026A1 (en) New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors
CA2551900A1 (en) Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors
ZA200306221B (en) Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors.
US20100015061A1 (en) Pharmaceutical Compositions Based on Anticholinergics and Andolast
US20050203088A1 (en) Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors
KR20050016999A (ko) 신규한 항콜린제 및 ｅｇｆｒ-키나제의 억제제를 기초로한 신규한 약물 조성물
US20060228305A1 (en) Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired